Contract
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Exhibit 10.13
A Technology Transfer and Clinical Supply Agreement
dated October 23, 2012 (Contract Number: BI: 63790), including all attachments,
amendments and addendums, if any
(the “AGREEMENT”)
has been concluded between
000 Xxxxxxxxx Xxxxx
Xxxxx 000
Xxxxxxx Xxxxxx, XX XXX 00000
(“CUSTOMER”)
on the one hand
and
Boehringer Ingelheim RCV GmbH & Co KG
[*]
(“BI RCV”)
on the other hand.
BI RCV herewith gives notice to CUSTOMER that the AGREEMENT with all rights and obligations will be assigned from BI RCV to its affiliate Boehringer Ingelheim Biopharma-ceuticals GmbH, Xxxxxx Xxxxxx 000, 00000 Xxxxxxxxx/Xxxxx, XXXXXXX, with effect from January 1st, 2014.
Boehringer Ingelheim Biopharmaceuticals GmbH accepts this transfer of the AGREEMENT with all rights and obligations resulting therefrom and consequently shall adopt BI RCV’s contractual position as per January 1st, 2014. BI RCV shall hereby be released from all rights and obligations of the AGREEMENT which occur on or after January 1st, 2014.
Notwithstanding the foregoing, the Quality Agreement for the respective project or product concluded between CUSTOMER and BI RCV will remain unaffected and BI RCV shall continue to assume all rights and obligations related to it.
CUSTOMER supplied materials (e.g. [*] etc.) shall continue to be delivered directly to BI RCV.
Page 1 of 2
| Vienna, 12.12.2013 | ||||
| Boehringer Ingelheim RCV GmbH & Co KG ppa. |
i. V. | |||
| [*] |
[*] | |||
| [*] |
[*] | |||
We hereby confirm and agree to the assignment of the AGREEMENT to Boehringer Ingelheim Biopharmaceuticals GmbH
| Ingelheim, | ||||
| Boehringer Ingelheim Biopharmaceuticals GmbH ppa. |
ppa. | |||
| [*] |
[*] | |||
| [*] |
[*] | |||
| Acknowleged: | ||||
| Redwood Shores, |
| Versartis, Inc |
| /s/ Xxxxxxx X. Xxxxxxx |
| Name: Xxxxxxx X. Xxxxxxx |
| Title: CEO |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Page 2 of 2
